Study to Compare the Effects of Viagra® Vs Hezkue® in Healthy Fasted Male Participants.
Condition(s) studied
Investigational drug(s) / intervention(s)
ASP-001: Oral liquid suspension of sildenafil
Viagra: Sildenafil film-coated tablet
ASP-001: Bottle/pump containing ASP-001 suspension
Study summary
The objective of this phase 1, open-label, single-center, two-way crossover trial is to evaluate the pharmacokinetics (PK), safety, and tolerability of 100 mg ASP-001 oral liquid suspension versus 100 mg Viagra (sildenafil citrate) tablets in fasted, healthy male volunteers
Eligibility
Primary outcome measure(s)
- Cmax — Baseline and at 24 different timepoints during the 24 hour post-dose
The PK profile of ASP-001 and Viagra in healthy male subjects. Calculation of maximum plasma concentration (Cmax) over the specified timeframe. - Absorption — Baseline and at several timepoints during the 24 hour post-dose
To determine if the rate and extent of absorption are similar for 100 mg of ASP-001 administered as 8 pumps of the 25 mg/mL oral liquid suspension of sildenafil compared to 100 mg Viagra (sildenafil) administered in the form of a film-coated tablet. - AUCt — Baseline and at 24 different timepoints during the 24 hour post-dose
The PK profile of ASP-001 and Viagra in healthy male subjects. Calculation of the area under the plasma concentration versus time curve will be calculated using the linear trapezoidal rule from the zero time point to the last quantifiable concentration (AUCt). - AUCi — Baseline and at 24 different timepoints during the 24 hour post-dose
The PK of ASP-001 and Viagra in healthy male subjects. The area under the plasma concentration versus time curve from zero to infinity (AUCi) will be calculated by adding the last quantifiable concentration (Ct)/ elimination rate contant (Kel) to AUCt. - Tmax — Baseline and at 24 different timepoints during the 24 hour post-dose
The PK of ASP-001 and Viagra in healthy male subjects. Calculation of the time of the maximum measured plasma concentration (Tmax). If the maximum plasma concentration occurs at more than one time point, the first is chosen as Tmax. - Kel — Baseline and at 24 different timepoints during the 24 hour post-dose
The PK of ASP-001 and Viagra in healthy male subjects. Calculation of the terminal elimination rate constant obtained from the slope of the line, fitted by linear least squares regression, through the terminal points of the log (base e) of the concentration versus time plot for these timepoints. - tHalf — Baseline and at 24 different timepoints during the 24 hour post-dose
PK of ASP-001 and Viagra in healthy male subjects. The half-life will be calculated by the equation tHalf = 0.693/ Kel. Apparent elimination half-life.
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Evolution Research Group, Clinical Pharmacology of Miami (CPMI) | Miami | Florida | |
| Evolution Research Group, Clinical Pharmacology of Miami (CPMI) | Miami | Florida |
More Aspargo Labs, Inc trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06782659 on ClinicalTrials.gov ↗ ← All trials in the USA